#Israel #Cancer Immunotherapy #Compugen #Holon #COM701

Compugen Reports Second Quarter 2025 Results

Compugen Ltd., a clinical-stage cancer immunotherapy company and pioneer in predictive computational target discovery using artificial intelligence and machine learning, recently announced its financial results for the second quarter of 2025. This report coincides with significant progress in its clinical trials, specifically regarding COM701, its investigational drug for platinum-sensitive ovarian cancer.

On July 2025, Compugen successfully dosed the first patient in the MAIA-ovarian trial, assessing COM701 as a maintenance therapy for those experiencing relapsed platinum-sensitive ovarian cancer. This bold step is part of a broader strategy to leverage innovative therapies in treating this challenging disease. Dr. Anat Cohen-Dayag, President and CEO, expressed excitement over this milestone, indicating the company's commitment to advancing its immuno-oncology program.

In conjunction with this trial initiation, Compugen is set to present pooled analysis from three previously reported Phase 1 trials of COM701 focused on platinum-resistant ovarian cancer at the upcoming ESMO 2025 conference in October. This presentation aims to bolster the existing data demonstrating the drug's potential efficacy and align with the company's efforts to gather robust clinical evidence.

Meanwhile, clinical recruitment continues for GS-0321 (previously known as COM503), a potential first-in-class antibody targeting IL-18 binding protein, which is being developed in collaboration with Gilead. This partnership reflects Compugen's strategic approach to harness collaborations for advancing groundbreaking cancer therapies.

Compugen's partner, AstraZeneca, is making strides with its rilvegostomig program, particularly notable for its advanced ten ongoing Phase 3 trials. This bispecific antibody incorporates the TIGIT component derived from Compugen's COM902 and is engineered to enhance immune responses against tumors. At the recent ASCO 2025 conference, early data presented by AstraZeneca showed promising results in various cancer settings, including non-small cell lung cancer (NSCLC). Plans for further updates on these trials will be outlined during the ESMO 2025 conference.

Financially, Compugen reported cash and cash equivalents of approximately $93.9 million as of June 30, 2025. This solid financial footing positions the company well, projecting that their current funds will sustain operations into 2027 without incurring debt. In terms of revenue, the company garnered approximately $1.3 million for the second quarter, significantly down from the previous year's $6.7 million, mainly due to the recognition timing of payments from licensing agreements.

R&D expenses remained relatively stable, reflecting a commitment to maintaining their pipeline. However, their net loss for the quarter was estimated at $7.3 million, compared to $2.1 million in the same period of 2024. Despite this increase, the company remains optimistic about its trajectory and potential future revenue from ongoing collaborations and clinical advancements.

Looking forward, Compugen has several critical milestones on the horizon, including results from a projected interim analysis of COM701 in late 2026. Additionally, the upcoming presentations at ESMO will provide crucial insights into the progression of both their own trials and those of their partners.

Dr. Cohen-Dayag anticipates new leadership dynamics with Dr. Eran Ophir transitioning into the CEO role in September and forming a robust strategy for driven growth and development in their therapeutic pipeline.

In conclusion, Compugen's Q2 2025 results showcase significant advancements in their clinical trial initiatives while solidifying their financial health. With a clear focus on innovation in cancer therapies, the future appears promising for the company and its stakeholders.